免疫检查点Tim-3和LAG-3在肺癌中的研究进展  

Progress in immune checkpoints Tim-3 and LAG-3 in lung cancer

作　　者：于悦 孔英君[1] 刘航 刘海洋[1] 李萌[1] 张敏[1] YU Yue;KONG Yingjun;LIU Hang;LIU Haiyang;LI Meng;ZHANG Min(Department of Respiratory Medicine,the First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院呼吸内科,黑龙江哈尔滨150001

出　　处：《现代肿瘤医学》2021年第18期3279-3282,共4页Journal of Modern Oncology

摘　　要：近年来肺癌的免疫治疗取得了重大突破,随着免疫检查点抑制剂的出现,阻断体内抑制性分子可以使免疫系统重新激活以抵抗肿瘤,改善了一线和二线治疗中的总生存率。目前细胞程序死亡受体1(PD-1)及其配体(PD-L1)抑制剂为肺癌患者提供了新的治疗方法。尽管检查点阻断改善了肺癌患者的治疗前景,但单药治疗方法仅对一部分患者有效且可能产生耐药性,仍需我们不断探索新的抑制途径。本文主要对免疫检查点T细胞免疫球蛋白黏蛋白分子-3(Tim-3)和淋巴细胞活化基因-3(LAG-3)在肺癌中的研究进展作一综述。In recent years,there is a major breakthrough of immunotherapy of lung cancer.With the appearance of Immune checkpoint inhibitors,blocking inhibitory molecules can reactivate the immune system,resist tumors and improve the overall survival rate in patients receiving first-line and second-line treatment.Currently programmed death-1(PD-1)and its ligand(PD-L1)inhibitors provide a new treatment for lung cancer patients.Although checkpoint blockade improves the treatment prospects of lung cancer patients,monotherapy is only effective in some patients and may develop resistance,therefore we still need to explore new inhibition pathways.This article reviews the research progress of T-cell immunoglobulin mucin-3(Tim-3)and lymphocyte activation gene-3(LAG-3)in lung cancer.

关 键 词：肺癌 免疫检查点 免疫治疗 TIM-3 LAG-3 

分 类 号：R734.2[医药卫生—肿瘤]